Wellington Management Group LLP Purchases New Position in Novartis AG $NVS

Key Points

• Wellington Management Group acquired 11,045 Novartis shares during the second quarter, worth approximately $1.73 million. Several other institutional investors also initiated positions, with institutions collectively owning 13.12% of the stock.
• Analyst sentiment is mixed: six analysts rate Novartis a Buy and ten rate it a Hold, resulting in an overall “Hold” consensus and a $153 average price target.
• Novartis faces increased investor scrutiny after late-stage drug-trial setbacks, including del-desiran’s failure, concerns over roughly $30 billion in acquisitions, and a shareholder call for board changes.

Wellington Management Group LLP acquired a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,045 shares of the company's stock, valued at approximately $1,731,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Pin Oak Investment Advisors Inc. acquired a new position in Novartis during the 2nd quarter worth approximately $196,000. North Star Asset Management Inc. purchased a new position in Novartis in the 2nd quarter worth approximately $965,000. Kahn Brothers Group Inc. acquired a new stake in Novartis in the second quarter valued at approximately $2,067,000. Dearborn Partners LLC acquired a new stake in Novartis in the second quarter valued at approximately $5,021,000. Finally, First Bancorp Inc ME purchased a new stake in shares of Novartis during the second quarter valued at approximately $57,000. Hedge funds and other institutional investors own 13.12% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Citigroup reissued a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Royal Bank Of Canada initiated coverage on shares of Novartis in a research note on Tuesday. They set a "sector perform" rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Novartis from a "buy" rating to a "hold" rating in a report on Tuesday. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research report on Friday, July 24th. Finally, HSBC set a $136.00 target price on Novartis in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $153.00.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: The stock showed signs of rebounding after its steep selloff, suggesting some investors may view the decline as an overreaction and remain confident in Novartis’s established medicines portfolio. Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
• Neutral Sentiment: Investors are focusing on how Novartis deployed roughly $30 billion in recent deals, as several acquired programs have encountered clinical setbacks. The scrutiny could lead to changes in capital-allocation priorities, deal approval processes or board composition. Focus: Novartis investors turn spotlight on M&A after trial setbacks
• Negative Sentiment: Experimental drug del-desiran failed to produce a statistically significant improvement in a late-stage trial for myotonic dystrophy type 1. The failure removes a potentially important growth asset and adds to concerns about Novartis’s pipeline. Drug Trial Setbacks Raise Questions Over Novartis’s Growth Pipeline
• Negative Sentiment: Del-desiran was the second major trial setback in a short period, contributing to a sharp weekly selloff and making investors question whether acquisitions are generating sufficient pipeline value. Deutsche Bank responded by cutting its view on the stock. Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks
• Negative Sentiment: A major shareholder has called for a board shake-up, arguing that stronger oversight is needed after the trial failures and share-price decline. The challenge adds reputational and execution risk for management. Major Novartis shareholder calls for board shake-up after drug trial setbacks

Novartis Stock Down 0.2%

NVS stock opened at $137.22 on Friday. Novartis AG has a twelve month low of $121.57 and a twelve month high of $170.46. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $261.84 billion, a P/E ratio of 20.70, a PEG ratio of 2.67 and a beta of 0.45. The firm has a 50 day simple moving average of $154.18 and a 200-day simple moving average of $153.00.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The firm had revenue of $14.95 billion for the quarter. On average, equities research analysts predict that Novartis AG will post 8.84 earnings per share for the current fiscal year.

About Novartis

Novartis AG NYSE: NVS is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company's portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.